Board and Management

Tim Lovell, PhD, MBA, GAICD: Tim is the founding Board Chairman and CEO of Calpain Therapeutics. Tim has led the acquisition and development of the current ophthalmic pipeline, and has been instrumental in securing finance for the development. He is an author of numerous scientific publications, an invited and accomplished speaker, and an internationally-renowned molecular modeller in the pharmaceutical (AstraZeneca) and not-for-profit biotech (Scripps Research Institute). Tim holds a PhD in Theoretical Quantum Chemistry and Molecular Modelling, an MBA specialising in entrepreneurial ventures, is a graduate of the Australian Institute of Company Directors and a member of the local Biotechnology Angels Group.

Hugo LeMessurier BSc(Hons), GAICD: Hugo is a Non-Executive Director, and an experienced entrepreneurial business leader with a proven track record of successfully implementing complex business solutions within an international environment. His expertise has assisted the building of sustainable small-to-medium enterprise (SME) businesses via strategic planning, sales and marketing, international business development and public company listing. For over a decade Hugo has held directorships and senior management positions in start-up, listed and multinational organisations in the USA, EU and Australia. He has worked in the biotechnology industry for over 20 years including 8 years in the USA and EU with Genzyme Corporation in senior sales and marketing positions. He regularly advises biotechnology companies and research organisations on technology commercialisation, licensing and partnering strategies. He holds a BSc in microbiology, immunology and genetics, is a Director of Cryptogen Pty Ltd, Director of Axxos Pty Ltd, Growth Mentor Pty Ltd, a member of the Australian Institute of Company Directors, AusBiotech, Australian Angel investment groups and is an active investor in early stage companies.

Wayne Irvine: Wayne is an Observer to the Board, and a founding owner / director of the Westside Group of companies operating in the commercial and industrial construction and facility management industry.  Specializing in building services his business units offer preventative maintenance, service, design and construction solutions in air-conditioning / mechanical and plumbing services.  The Westside team has over one hundred staff with an annual turnover in excess of 40 million dollars. He is a certified Mediator and an Adjudicator for South Australia’s Security of Payment Act. More than 20 years of senior business management together with formal training and practical experience has provided Wayne with a passion to share a wealth of developed intellectual property with likeminded business people and entrepreneur’s.  Following an investment through his involvement with a South Australian Angels Group, Wayne sits as an observer on the board for Calpain Therapeutics Pty. Ltd. representing his group of investors. 

Matthew Worrell, CPA: Matthew is the company Secretary and founded Worrell & Co in 2003 and has been working in the accounting industry for the last 21 years. He is a certified practising accountant and specialises in business consulting, self-managed super funds and taxation.

Ophthalmology Advisory

Professor Robert Casson, MBBS (Hons), DPhil, FRANZCO: Professor Robert Casson MB,BS (Hons), M.Biostatistics, DPhil, FRANZCO is the Head of the Discipline of Ophthalmology and Visual Science at Adelaide University. He is an internationally recognized ophthalmic clinician/scientist with special interests in glaucoma, retinal cell biology, neuroprotection, ophthalmic epidemiology and translational ophthalmic research. After completion of a laboratory-based DPhil in 2004 he returned to Australia and established the South Australian Institute of Ophthalmology (SAIO), including the Ophthalmic Research Laboratory co-located with Neuropathology in the Hanson Institute. His laboratory recently moved to the state-of-the-art Adelaide Health and Medical School. He is a founding board member and Vice-Chair of the ophthalmologist-led, evidence-based NGO, Sight for All, and serves as their Chief Scientific Advisor. In 2012, he completed a Masters of Biostatistics at Adelaide University.

Professor Keith Martin (Cambridge), MA BM BCh DM MRCP FRCOphth ALCM: Keith Martin was elected as the first Professor of Ophthalmology at the University of Cambridge in 2010. He is Head of Ophthalmology at the University of Cambridge, Deputy Director of the University’s John van Geest Centre for Brain Repair and an Affiliate Principal Investigator at the Wellcome Trust - MRC Cambridge Stem Cell Institute. He is also Academic Lead for Ophthalmology and Lead Clinician for Glaucoma at the Cambridge University Hospitals NHS Foundation Trust.  He graduated from the University of Cambridge with a 'Triple First' in Medical Sciences and Neuroscience before completing clinical Training at Oxford University Clinical School, Ophthalmology Residency in Cambridge and Clinical and Research Fellowships in Glaucoma at Moorfields Eye Hospital in London and the Wilmer Eye Institute in Baltimore. Professor Martin established and runs the Glaucoma Research Laboratory at the University of Cambridge, working to develop new treatments for eye disease using stem cells, gene therapy and other techniques.  In 2010, Professor Martin won the ARVO Foundation for Eye Research Translational Research Award, an international prize to a researcher from any country under the age of 50 years whose research is judged to have the potential to lead to major breakthroughs in the treatment of eye disease. He was also a winner of the World Glaucoma Association Senior Clinician Scientist Award in 2011 and was awarded the Duke Elder Medal by the Royal College of Ophthalmologists in 2017. Clinically, Professor Martin specialises in the medical and surgical management of complex glaucoma in adults and children. He is President of the World Glaucoma Association from January 2018. 

Professor Jeff Goldberg (Stanford): Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University. His clinical effort is focused on patients in need of medical or surgical intervention for glaucoma and other retinal and optic nerve diseases, as well as cataract. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies, and his laboratory is developing novel stem cell and nanotherapeutics approaches for eye repair. Dr. Goldberg received his B.S. magna cum laude from Yale University, and his M.D. and Ph.D. from Stanford University where he made significant discoveries about the failure of optic nerve regeneration. He did his clinical training in ophthalmology and then in glaucoma at the Bascom Palmer Eye Institute, and was awarded a fellowship from the Heed Foundation. He was named the 2010 Scientist of the Year by the Hope For Vision foundation, and received the Cogan award from the Association for Research in Vision and Ophthalmology in 2012. He was elected in 2010 to the American Society of Clinical Investigation, an honorary society of physician scientists. He directs an NIH-funded research laboratory and has developed significant expertise with implementing FDA IND clinical trials for optic nerve neuroprotection and regeneration. His goal is to translate scientific discoveries to patient therapies.

Professor Len Levin (McGill): Dr. Leonard Levin is a tenured professor in the Departments of Ophthalmology and Neurology & Neurosurgery at McGill University, and chair of the Department of Ophthalmology. He is a physician-scientist at the Neuro, where he does research related to optic nerve diseases and related disorders. Dr. Levin received a bachelor’s degree magna cum laude in applied mathematics at Harvard, where he did an honors thesis designing a language for computer-assisted music composition. He did his MD in the Harvard/MIT joint program in Health Science and Technology, with a PhD in neurobiology, focusing on research relevant to multiple sclerosis. He then pursued an ophthalmology residency and neuro-ophthalmology fellowship at the Massachusetts Eye and Ear Infirmary at Harvard. His research program focuses on mechanisms of retinal ganglion cell death at the molecular, tissue culture, and whole animal level. This includes the role axonal damage plays in inducing loss of retinal ganglion cells and how axons themselves undergo injury, an area common to ophthalmology and neurology. He is particularly interested in using advanced imaging techniques to study signaling of cell death in the retina and the development of new drugs for optic nerve and retinal disease. This and related research has resulted in more than 170 peer-reviewed papers, reviews, and book chapters, 4 issued patents, and his editing of five textbooks in the visual sciences or ophthalmology, including Ocular Neuroprotection, Neuroprotection for Glaucoma: A Pocket Guide, and Adler’s Physiology of the Eye. He is past chair of the Diseases and Pathophysiology of the Visual System study section at the United States National Institutes of Health and has been an ad hoc reviewer for the Canadian Institutes of Health Research, and funding bodies in Britain, Hong Kong, Israel, Australia, and elsewhere. He currently chairs the Executive Scientific Oversight Committee for the Audacious Goals Initiative at the USA National Eye Institute.

Dr. Ted Lend (Stanford): Theodore Leng, MD, MS, is regarded as one of top 150 innovators in medical and surgical retina. He is currently the Director of Clinical and Translational Research and the Director of Ophthalmic Diagnostics at the Stanford University School of Medicine Department of Ophthalmology. Dr. Leng received his medical degree from the Stanford University School of Medicine and completed his ophthalmology residency at Bascom Palmer Eye Institute and has been named one of “America’s Top Ophthalmologists” by the Consumers’ Research Council of America. He is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. He is also an active member of the Association for Research in Vision and Ophthalmology, the Retina Society, the Macula Society, the Vit-Buckle Society, as well as the American Society of Retina Specialists.

Dr. Keith Barton (Moorfields): Keith Barton is a Consultant in the Glaucoma Service at Moorfields Eye Hospital in London and Honorary Reader at University College London’s Institute of Ophthalmology. He qualified in Medicine in Belfast, Northern Ireland, having also obtained an intercalated First Class Honours BSc in Medical Microbiology. Dr Barton completed his residency training at Moorfields Eye Hospital and fellowship training at the Bascom Palmer Eye Institute, University of Miami School of Medicine after which he was appointed to the Glaucoma Service at Moorfields in 1996, becoming director in 2005 for 6 ½ years. His main clinical and research interest is the surgical management of glaucoma, especially uveitic and other secondary glaucomas. He has a particular interest in the use of Aqueous Shunt Devices and has been an investigator and steering group member of a number of internationally renowned trials, including the Tube versus Trabeculectomy and Primary Tube versus Trabeculectomy Studies. In addition, he co-chairs the Ahmed Baerveldt Comparison Study and is a member of the trial management committees of two UK government funded surgical trials, the Lasers in Glaucoma and Ocular Hypertentsion (LIGHT) Study and Treatment of Advanced Glaucoma (TAGS) Study. Dr Barton has authored over 100 peer-reviewed publications and book chapters, as well as reviewing for 17 ophthalmic journals. In 2014 he became Editor-in-Chief of the British Journal of Ophthalmology and is an editorial board member of 3 other journals. He has been visiting professor at New York Eye and Ear Infirmary, University of Florida, University of North Carolina, University of California, San Diego and has served as Hong Leong Visiting Professor, National University of Singapore from 2011 to 2014. Keith Barton co-founded the Ophthalmology Futures Forums. 

Dr. Graham Fraenkel, BMBS FRACS FRANZCO: Dr. Graham Fraenkel is a Fellow of the Royal Australasian College of Surgeons and a Fellow of the Royal Australian and New Zealand College of Ophthalmologists. Dr Fraenkel is a member of the American Society of Cataract and Refractive Surgeons. He has been a Senior Clinical Lecturer with the University of Adelaide teaching cataract and corneal surgery. Dr Fraenkel special interests are in the areas of cataract surgery, refractive & corneal surgery. He has published an impressive list of academic papers and participated in a number of research projects. Dr Fraenkel has also established an enviable reputation as a lecturer. Dr Fraenkel was the first Ophthalmologist in Australia to join The Fred Hollows Foundation’s International Mentoring and Fund Raising Programme. 

Dr. James Muecke, MBBS (Hons), FRANZCO: Dr. James Muecke is a Cataract and Ocular Oncology surgeon and the Sight-For-All Charity’s founding Chairman and an internationally recognised Cataract Ophthalmologist. Very recently, James was the recipient of an award from the Australia Pacific Ophthalmology Association for services to cataract surgery in preventing blindness in developing countries.

Pharmaceutical / Regulatory / Toxicology / Formulation Advisory

Professor Evan Siegel, PhD: Dr. Siegel founded Ground Zero Pharmaceuticals (GZP) in 1999 from his consulting firm, Ground Zero Strategics, Ltd.  Dr. Siegel has held positions as a Toxicology Reviewer at the US Food and Drug Administration and Food and Drug Branch, California Department of Health Services and, at the latter, was Supervising Toxicologist and Chief of Special Services. He has served in regulatory affairs and executive positions in both the pharmaceutical industry (Astra, Syntex, Medical Science Systems and OXO Chemie) and trade association environments. He attended the Waksman Institute of Microbiology where he earned both his Master and Doctor of Philosophy degrees in Virology and Molecular Biology. He is an Adjunct Professor in the Centre for Integrated Preclinical Drug Development, University of Queensland, Australia. Dr. Siegel is the Chairman of the GZP Board of Directors.

Des Williams, PhD: Dr. Des Williams has had a total of 23 years in the pharmaceutical industry in various roles, which has included seven years in the Research and Development Group, Faulding Pharmaceuticals, and many consultancies in the pharmaceutical industry in Australia and various international jurisdictions, including the CSIRO. His research work has focused on understanding the biochemical basis and dietary factors of colorectal cancer (in collaboration with CSIRO), formulation of new pharmaceutical compounds and their evaluation (preclinical and clinical). Des is a member of the Pharmaceutical Subcommittee, Advisory Committee for Prescription Medicines, within the Therapeutic Goods Administration (TGA) in Canberra.  

Rae West, PhD: Rae West is a highly-trained clinical research professional with range of skills developed during 20+ years working in the pharmaceutical, biotechnology and clinical consulting industries. She has successfully managed all phases of clinical trials conducted at Australian and overseas investigational sites, including Contract Research Organisation (CROs), planning, monitoring and reporting of First-in-Human (FIH) Phase I and bioequivalence/bioavailability (BE/BA) studies. She has trained professionals to internationally recognised regulatory and ethical standards required to conduct trials using procedures in compliance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. Her experience covers Food and Drug Administration (FDA) meeting submissions with knowledge of the preclinical toxicology and safety pharmacology studies required to support initial human trials of new chemical (molecular) entities.  

Chemistry Advisory

Professor Andrew Abell, PhD: Andrew is Co-Founder and Principal Scientific Advisor to Calpain Therapeutics and was the chemistry inventor of the proprietary class of compounds that Calpain Therapeutics holds in its portfolio. Andrew is also Professor of Chemistry at Adelaide University, Australia. He is an expert on the design and synthesis of protease inhibitors, author of more than 140 peer–reviewed publications and three patents, and he has led research grants totalling more than $10 million in the last 10 years. His international standing has been recognised with the award of the NZIC Easterfield medal and his being an elected Fellow of the New Zealand Institute of Chemistry and the Royal Australian Institute of Chemistry, a member of the Australian Research Council College of Experts, and the award of adjunct Professorships with the University of Canterbury and Lincoln University.  Andrew is an Editor of international chemistry journals and two books on peptidomimetics and he provides 20 years of continuous research support for design and synthesis of protease inhibitors and other therapeutic agents.

Business Advisory

Andrew Bollen, PhD: Andrew Bollen was most recently an Executive Director at Playford Capital Pty Ltd. He has worked in high technology research and development, start-up management, investment banking, portfolio management, and venture investing in Australia, the United States, and Asia. He has played a key role in raising substantial funds for start-ups, serving on their boards, helping to manage their growth and structuring and negotiating public and private transactions. Andrew is a Director of Cavitus Pty Ltd, Embertec Pty Ltd, NVT Systems Pty Ltd, and Reproductive Health Science Pty Ltd. He holds a PhD in Artificial Intelligence from The Australian National University and also a BSc from The University of Adelaide.